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A B S T R A C T
The natural CD25+ FOXP3+ regulatory T cell (Treg) population is generated as a distinct lineage in the thymus,
but the details of Treg development in humans remain unclear, and the timing of Treg commitment is also
contested. Here we have analyzed the emergence of CD25+ cells at the CD4+CD8+ double positive (DP) stage
in the human thymus. We show that these cells share T cell receptor repertoire with CD25+ CD4 single-positive
thymocytes, believed to be committed Tregs. They already have a fully demethylated FOXP3 enhancer region
and thus display stable expression of FOXP3 and the associated Treg phenotype. Transcriptome analysis also
grouped the DP CD25+ and CD4 CD25+ thymocytes apart from the CD25− subsets. Together with earlier
studies, our data are consistent with human Treg commitment already at the DP thymocyte stage. We suggest
that the most important antigens and signals necessary for human Treg diﬀerentiation may be found in the
thymic cortex.
1. Introduction
The best-characterized population of regulatory T cells is deﬁned by
the stable expression of the forkhead/winged-helix transcription factor
FOXP3, which promotes and sustains the Treg cell phenotype and
function [1–3]. The importance of FOXP3 and Treg cells to the main-
tenance of immunological tolerance is provided by immune dysregu-
lation, polyendocrinopathy, enteropathy and X-linked syndrome
(IPEX), an early and severe form of autoimmunity caused by loss-of-
function mutations in FOXP3 [4,5]. The natural Tregs develop in the
thymus, and the current data suggest that they form a lineage distinct of
conventional T cells. The epigenetic stabilization of FOXP3 expression
is also imprinted in the thymus, and provides a key distinguishing
marker of stable Treg phenotype in the periphery [6]. The human
FOXP3 locus contains the promoter region and three conserved non-
coding regions (CNSs) that regulate the FOXP3 expression. CNS2 also
known as Treg-speciﬁc-demethylated region (TSDR) is a CpG-rich in-
tronic enhancer region that is completely demethylated in natural Tregs
but methylated in conventional T cells and activated T cells that can
transiently upregulate FOXP3 [7].
Most of the data on thymic Treg development is based on murine
models. Extensive literature suggests that autoreactive thymocytes
escaping clonal deletion can be diverted to the Treg lineage, and Tregs
would thus form a suppressive population speciﬁc to self-antigens
[8–12]. In support of this scenario the TCR repertoire of conventional T
cells and Tregs has been reported to be largely distinct [13], with a
recent study on the murine thymus reporting only a 6% overlap [14].
However, Tregs can also be speciﬁc to non-self-antigens, and using
TCRs obtained from Treg cells as transgenes can result in ineﬃcient
thymic Treg generation, indicating that TCR aﬃnity alone is not en-
ough to determine commitment to Treg lineage [15,16]. Indeed, it is
possible the Treg diﬀerentiation requires a succession of suitable TCR
signals, instead of a unitary contact [12]. The current scenario holds
that TCR-mediated signals, probably modiﬁed by costimulatory mole-
cules, ﬁrst lead to upregulation of the high-aﬃnity IL-2 receptor CD25.
Interleukin-2 then provides an essential and largely nonredundant
second signal for the upregulation and stabilization of FOXP3 expres-
sion [17,18].
The timing of Treg commitment remains unclear. It has been sug-
gested that in mice the commitment takes place only in medulla, at the
CD4 single-positive stage. The great majority of FOXP3+ thymocytes
are conﬁned to the medulla and in intrathymic transfer experiments the
SP cells showed the greatest propensity for Treg diﬀerentiation [19,20].
Moreover, IL-2 availability may also present limitations, depending on
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localization of IL-2 sources [21,22]. For example, it has been reported
that paracrine production of IL-2 by the most mature conventional SP
thymocytes may be important, and these cells are not found in the
thymic cortex [23]. Thus it may be that Treg commitment may be de-
pendent on a limited number of suitable medullary niches.
The existing data in humans, although scarce, is consistent with
commitment already at the cortical DP stage [24,25]. FOXP3 expression
is ﬁrst found already at the CD4-CD8- stage, but becomes more pro-
nounced at the DP stage [26,27]. The cortical FOXP3+ cells are mainly
found in the most mature, CD3high CD4+CD8+DP population, and
they express high levels of CD69, a marker of positively selected cells
[28,29]. The level of FOXP3 expression is as high as that found in the
medullary CD4 SP cells, and the FOXP3+ DP cells also express several
Treg-associated molecules and are capable of suppressive function in
vitro [24,28,30–32]. Moreover, linear regression analysis reported by
Nunes-Cabaco et al points to the FOXP3+ DP population as the major
contributor to the FOXP3+ CD4 SP subset [24].
In the present report we show that the FOXP3+ represent a distinct
lineage already at the DP stage, with strong similarity to the FOXP3+
CD4 SP subset in terms of TCR repertoire, TSDR demethylation and
transcriptomics. These data provide further support for the DP stage as
the crucial point of divergence in human Treg cell development.
2. Materials and methods
2.1. Patient samples
Thymic tissue was obtained from 13 otherwise healthy children (3
males, 10 females) undergoing corrective cardiac surgery. The children
had no known immunological or genetic abnormalities. The tissue is
routinely removed for improved exposure during cardiac surgery. The
children were from 0.0 to 9.3 years old (mean 1.2 year, median 0.3).
The pediatric ethics committee of Helsinki University Hospital ap-
proved the study, and an informed consent was obtained from the
parents of the children. The study was performed in accordance of the
Declaration of Helsinki.
2.2. Cell isolation and cell sorting
Thymocytes were released within 6 h of the thymectomy from the
thymus tissue sample by mechanical homogenization. The antibodies
used in the ﬂow cytometry were direct ﬂuorochrome conjugates: CD3-
PE, CD8-APC, CD3-FITC, CD69-APC (Immunotools, Friesoythe,
Germany), CD25-PE (clone M-A251), CD4-APC-Cy7, CD8-PE-Cy7
(Beckton Dickinson, San Jose, CA), CD25-PE-Cy7 (clone BC96) and
CD4-Paciﬁc Blue (eBioscience, San Diego, CA). Since permeabilization
cannot be used with the cell sorting, Treg-associated marker CD25 was
used instead of FOXP3. Previous studies have shown that at the DP
stage roughly half of FOXP3+ cells express CD25, while most of
CD25high thymocytes are FOXP3+ [25,28].
Flow cytometry and sorting was performed using the FACSAria II
instrument. Fluorescence compensation settings were optimized by
using BD Bioscience CompBeads (Beckton Dickinson, San Jose, CA).
During sorting we performed a strict doublet exclusion using ﬂow cy-
tometric height and width parameters [33].
2.3. Genomic DNA extraction and sequencing
Frozen sorted samples were analyzed by Adaptive Biotechnologies
(Seattle, USA). Genomic DNA was extracted using the QIAsymphony
system, according to the manufacturer’s instructions (Qiagen,
Germany). The amount of DNA and the quality of samples were veriﬁed
before sequencing. The TCRβ chain was sequenced using the
ImmunoSEQ assay (Adaptive Biotechnologies) and Illumina platform as
previously described [34]. Repertoire data analysis was done using the
ImmunoSEQ analyzer toolset.
2.4. Methylation analysis
Demethylation status of the TSDR was determined by bisulﬁte
conversion of demethylated cytosines, followed by quantitative PCR, as
previously described [35]. Bisulﬁte conversion was performed with
Qiagen Epitect, according to the manufacturer’s instructions. Real-time
quantitative PCR was performed with Bio-Rad iCycler (Hercules, CA).
2.5. RNA sequencing
The transcriptome analysis was based on the Drop-seq protocol
[36]. RNA was mixed with Indexing Oligonucleotides (Integrated DNA
Technologies) and cDNA synthesized using the Maxima H- RTase (all
ThermoFisher Scientiﬁc). After PCR ampliﬁcation the amplicons were
tagged using the Nextera XT reaction (Illumina) and again ampliﬁed.
The concentration of the libraries was measured using a Qubit 2 ﬂuo-
rometer (Invitrogen) and the Qubit DNA HS Assay Kit (ThermoFisher
Scientiﬁc). The quality of the sequencing libraries was assessed using
the LabChip GXII Touch HT electropheresis system (PerkinElmer), with
the DNA High Sensitivity Assay (PerkinElmer). Sequencing of the li-
braries was performed at the Functional Genomics Unit of the Uni-
versity of Helsinki, Finland, using the Illumina NextSeq 500. Subse-
quently, the original pipeline suggested in Macosko et al. was used
[36]. Brieﬂy, reads were additionally ﬁltered to remove polyA tails of
length 6 or greater, then aligned to the human (GRCh38) genome using
STAR aligner [37] with default settings. Uniquely mapped reads were
grouped according to the 1–8 barcode, and gene transcripts were
counted by their Unique Molecular Identiﬁers (UMIs) to reduce the bias
emerging from the PCR ampliﬁcation. Digital expression matrices
(DGE) reported the number of transcripts per gene in a given sample
(according to the distinct UMI sequences counted).
3. Results
3.1. Sample preparation and sequencing of TCR genes
To analyze the relationship between FOXP3+ DP and CD4SP sub-
sets we used ﬂow cytometric sorting to isolate them, with CD25 as a
surrogate cell-surface marker for the intracellular FOXP3. The CD25-
counterparts were isolated, as well. Altogether 5 thymus samples were
analyzed (samples A-E), obtained from otherwise healthy children un-
dergoing corrective cardiac surgery. To exclude any major thymic ab-
normalities we measured the frequency of the main thymocyte subsets.
All samples showed the typical distribution of CD4/CD8 double nega-
tive (mean 1.2%, range 0.6–1.5%), double-positive (79.9%, range
75.1–83.3%), CD4+ single-positive (9.8%, range 6.3–16.5%), and
CD8+ single-positive cells (9.0%, range 7.1–11.7%). As expected, most
double-negative thymocytes were CD3- (data not shown), double-po-
sitive cells showed a distribution ranging from CD3- to CD3high, and the
single-positive subsets were almost completely CD3high (Fig. 1). The
mean frequency of CD25+ cells was 0.7% (range 0.5–0.9%) in the DP
population and 14.2% (range 11.9–15.7%) in the CD4SP population.
In addition to the CD25+ subsets, in samples A and B the DP subset
was also divided into CD3high and CD3low cells, while in samples C-E the
CD25− DP subset was isolated as one. The purity of CD25+ subsets
was on average 96.9% ± 5.8% in DP population and 95.4%±2.5% in
CD4SP population. The number of cells obtained varied according to
the frequency of the subset in question (Table 1). Genomic DNA was
extracted from the isolated subsets and the complementarity de-
termining region 3 (CDR3) sequences of TCRβ ampliﬁed and se-
quenced. The number of TCRβ reads obtained ranged from as low as
2000 in the DP CD25+ population (sample D) to as high as 3.5 × 106
in the DP CD3high population (sample A), again largely dictated by the
frequency of the subset in question. The number of unique productive
TCRβ sequences ranged from 600 to 50 000 (see Table 1).
Consistent with the previously reported selection for shorter CDR3
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lengths during thymic selection, the CDR3 was shorter in productive
than in nonproductive rearrangements, and in more mature subsets. At
the DP stage the mean length of productive CDR3 recombinations was
45.6 bp, while in the CD4SP stage the length was 43.7 bp and 44.3 bp in
CD25− and CD25+ cells, respectively. Within the DP population, the
CD3low stage had a CDR3 length of 46.5 bp, the CD3high stage 44.2 bp.
Interestingly, the shortest CDR3 was found in the DP CD25+ subset
(43.4 bp) (Table 2, Fig. 2). Since TCR-dependent selection in the
thymus has been shown to drive CDR3 shortening, the fact that DP
CD25+ and CD4 SP CD25+ subsets had a similar CDR3 length suggests
the absence of major TCR-dependent selection events between these
subsets.
3.2. DP CD25+ and CD4 CD25+ thymocytes have overlapping TCR
repertoire
To track the developmental pathway of the regulatory T cells at the
DP stage we then measured the relative overlap in TCR repertoire be-
tween the isolated subsets. As a determinant of overlap we used the
overlap coeﬃcient, obtained by dividing the number of shared se-
quences by the smaller of the size of the two sets. The data were ana-
lyzed at both nucleotide and amino acid level. In particular, overlap in
identical nucleotide sequences is likely to reveal cells of common clonal
background, whereas identical amino acid sequences encoded by dif-
ferent nucleotide sequences may also indicate convergent recombina-
tion or selection.
Given the small number of sequences obtained from some of the
isolated subsets, especially the relatively infrequent DP CD25+ cells,
the overlaps were generally small. However, analysis of unique pro-
ductive nucleotide sequences showed that strongest aﬃnity of the DP
Fig. 1. Flow cytometric analysis of a representative thymus sample (C). A.
Thymocyte gating and distribution of main thymocyte subsets. The data is
shown on logarithmic scale, except for forward scatter (FS). The frequency of
each main subset is indicated in the ﬁgure. B. CD3 expression pattern in DP and
CD4SP thymocytes. C. CD25 expression pattern in DP and CD4SP thymocytes.
DN: CD4/CD8 double-negative, DP: CD4/CD8 double-positive.
Table 1
Sequencing results of TCRβ genes in the samples A-E.
Age and gender Population Cell count Total reads In-frame In-frame % Unique in-frame
A 3 years 3 months, female DP CD25+ 27 000 482 609 387 339 80.3 7660
CD4+ CD25+ 100 000 1 250 729 1 037 326 82.9 24 958
DP CD3high 300 000 3 557 300 2 921 600 82.1 50 047
DP CD3low 1 million 113 693 81 455 71.6 581
CD4SP 1 million 111 568 78 940 70.8 616
CD8SP 1 million 129 274 96 899 75.0 974
B 2 months, female DP CD25+ 10 000 176 460 132 387 75.0 2412
CD4+ CD25+ 120 000 2 309 773 1 882 086 81.5 28 828
DP CD3high 190 000 1 830 345 1 554 601 84.9 26 782
DP CD3low 1 million 84 453 68 927 81.6 1252
CD4SP 1 million 63 764 45 319 71.1 735
CD8SP 1 million 4 443 726 3 723 236 84.0 99 631
C 1 year 4 months, female DP CD25+ 32 000 3416 2611 76.4 2289
DP CD25− 1 million 40 632 36 236 79.1 28 661
CD4+ CD25+ 132 000 15 207 12 086 79.5 10 721
CD4+ CD25− 108 000 13 500 10 719 79.4 9669
D 2 weeks, male DP CD25+ 21 000 2642 1891 71.6 1751
DP CD25− 1.2 million 67 610 51 826 76.7 47 456
CD4+ CD25+ 182 000 19 091 14 279 74.8 13 293
CD4+ CD25− 164 000 13 541 10 185 75.2 9482
E 7 months, male DP CD25+ 21 000 2212 1698 76.7 1571
DP CD25− 520 000 30 090 24 585 81.7 22 808
CD4+ CD25+ 93 000 7741 6254 80.8 5889
CD4+ CD25− 112 000 10 261 8412 82.0 7885
Table 2
Average CDR3 length in the thymus samples A-E.
Nonproductive 46.2 ± 1.0
DP CD3low 46.5 ± 1.1
DP CD3high 44.2 ± 0.5
DP CD25− 45.6 ± 1.2
DP CD25+ 43.4 ± 0.6
CD4 CD25- 43.7 ± 0.5
CD4 CD25+ 44.3 ± 0.1
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CD25+ subset was with the CD4SP CD25+ subset (0.016), followed by
the DP CD25- subset (Fig. 3). When the number of reads was taken into
account, providing information on the clonal abundance, the overlap
between DP CD25+ and CD4SP CD25+ subsets was even more pro-
nounced (0.039). Notably, the two CD25+ populations were also clo-
sest to each other in nonproductive nucleotide repertoire. Since the
nonproductive sequences do not result in an expressed protein, they are
not subject to thymic selection and reﬂect the original recombination
process. The fact that the CD25+ subsets shared identical non-
productive nucleotide sequences thus further suggests that they have a
shared clonal origin.
Analysis of amino acid sequences were largely similar to the nu-
cleotide repertoire, with the biggest overlap found between the DP
CD25+ and CD4SP CD25+ populations in both unique amino acid
sequences and in total reads. However, the overlap between CD25+
and CD25- DP subsets was somewhat larger than observed in the nu-
cleotide sequences.
We then looked separately at the DP CD3low subset, isolated from
thymus samples A and B. At this stage no CD25+ cells were observed,
and we found no shared nucleotide sequences between DP CD25+ and
DP CD3low cells. Together, these data suggest a chain of clonal ma-
turation from DP CD3high to DP CD25+ and then CD4SP CD25+ po-
pulation.
3.3. Methylation analysis of DP and CD4SP CD25+ thymocytes
We have previously shown that on a single-cell level the expression
of FOXP3 is equally high in DP and CD4SP thymocytes [28,38]. How-
ever, the epigenetic status of the TSDR has been shown to be essential in
stabilizing Treg phenotype, and perhaps even more important than
FOXP3 expression as such [39]. To test the demethylation status of the
developing Tregs at the DP and CD4SP stage in the human thymus, we
sorted four thymus samples (thymus samples F-I, all donors were fe-
male) to obtain DP CD25+ and CD4SP CD25+ populations and their
CD25- counterparts. We then isolated genomic DNA for bisulﬁte con-
version of demethylated cytosines to uracil and used methylation-de-
pendent primers to amplify the TSDR. Quantitative real-time PCR
showed high methylation state in both CD25- subsets (mean ΔCt of
6.2 ± 0.2 in the DP CD25- and 6.0 ± 0.1 in CD4 CD25- cells) (Fig. 4).
The CD25+ subsets, in contrast, showed a clear pattern of demethy-
lated TSDR, with clearly lower mean ΔCt values. Most importantly,
there was no diﬀerence between the DP CD25+ (0.8 ± 0.2) and
CD4SP CD25+ (0.8 ± 0.6) subsets. Thus, a stable Treg phenotype can
be detected already at the DP stage.
3.4. Diﬀerential gene expression analysis of DP and CD4SP Tregs
To further track the developmental pathway of thymic regulatory
populations we compared the transcriptome of CD25+ and CD25−
cells in the DP and CD4SP subsets, isolated from further four thymus
Fig. 2. CDR3 length distribution in the thymic subsets. CDR3 length distribution of productive TCRβ rearrangements. Shorter CDR3 recombinations are detected
during thymic selection in more mature populations.
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samples (J-M). We ﬁrst used edgeR Bioconductor analysis package to
look for diﬀerential gene expression between the populations, and
calculated the diﬀerence as Log2fold change. Strikingly, no statistically
signiﬁcant diﬀerence between DP CD25+ and CD4SP CD25+ cells was
found in any of the genes identiﬁed. We then used the expression data
to construct a phylogenetic table and a principal components analysis
(PCA) of the relationship between the 16 samples (Fig. 5). Six of the
CD25+ samples grouped together, while one DP CD25+ (thymus M)
and one CD4SP CD25+ (thymus L) grouped among the CD25- samples.
Notably, there was no clear distinction between the DP CD25+ and
CD4SP CD25+ subsets. In the PCA the CD25+ samples were likewise
interspersed, while clearly diﬀerent from the CD25- subsets. These si-
milarities were based on overall gene expression pattern; no speciﬁcally
Treg-associated genes were detected, most likely because of the small
size of the samples.
Fig. 3. TCRβ repertoire overlap between the main thymocyte subsets. The
overlap is shown as overlap coeﬃcient of productive sequences. A. unique
nucleotide sequences. B. total nucleotide sequence reads. C. unique amino acid
sequences. D. total amino acid sequence reads. The thickness of each con-
necting bar indicates the degree of overlap relative to the overlap between
CD25+ DP and CD25+ CD4 SP subsets, which is shown as a ﬁxed thickness.
The overlap coeﬃcients are shown as numbers beside the bars. n = 5.
Fig. 4. The methylation status of TSDR in the CD25+ and CD25− thymocyte
populations. The degree of methylation was measured using methylation-sen-
sitive primers and real-time quantitative PCR. The data are shown on a relative
scale as change of Ct: ΔCt = Ct (demethylated DNA) – Ct (methylated DNA).
Each bar indicates mean value, the error bars SD (n = 4). ***p < 0.001.
Fig. 5. Phylogenetic transcriptome analysis of the relationship between the
CD25+ and CD25− thymocyte populations. A. The data are shown as a
heatmap and cladogram indicating the closeness of the transcriptome. The color
key is shown in the ﬁgure. The letters before the subset designations refer to
thymus samples J-M. B. A principal components analysis (PCA) of the re-
lationship between the thymus samples J-M.
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4. Discussion
Details of the developmental pathway of regulatory T cells remain
debated, and particularly little is known of human thymus. The pre-
ponderance of data in both species suggests that natural Tregs and
conventional T cells form distinct lineages, and our repertoire analysis
indicates that in humans this distinction is made at the DP CD3high
stage. Thereafter, the DP CD25+ thymocytes possess the hallmarks of
stable Treg lineage: They express high levels of FOXP3 as well as other
Treg-associated markers [24,30,32], share transcriptome features with
medullary CD4SP CD25+ Treg cells, display capability for suppressive
function [31], and their FOXP3 TSDR is fully demethylated. It should be
noted that our data do not exclude the possibility that part of the ma-
ture natural Treg population is converted at the CD4SP stage. Also, it is
possible that some of the CD4SP cells actually represent mature re-en-
trants from the periphery. However, previous work by Nunes-Cabaco
identiﬁed DP CD25+ thymocytes as the main source of CD4SP CD25+
population [24], and our data show much higher sequence overlap
between DP CD25+ and CD4SP CD25+ cells than between the me-
dullary CD4SP subsets. It should also be noted that the DP FOXP3+
population is quite substantial, accounting for 18% of the FOXP3+
thymocyte population [27].
Similarly to murine Treg cells, it is likely that the divergence to Treg
lineage is linked to TCR-mediated signalling. The FOXP3+ population
expresses high levels of CD5 and CD69, markers associated with posi-
tive selection, and they are also CD3high [28,29]. Our data on CDR3
length provides another approach to identify the role of TCR-mediated
selection. Previous studies in both mice and humans have shown that
during thymic selection the CDR3 gets progressively shorter, and this
shortening has been linked to MHC-TCR interactions [40–42]. It thus
reveals mainly the impact of positive selection. Our results show a
major decrease during the DP stage, and the CDR3 of DP CD25+ cells
was actually shorter than that of CD4SP CD25+ cells. This suggests that
positive selection of and commitment to the Treg lineage mostly takes
place at the DP stage. Whether the events leading to Treg commitment
start already earlier remains unclear. In humans FOXP3+ cells are
found already at the CD4-CD8- stage of thymic development [26], and
murine studies have shown that Treg phenotype can be established
even before FOXP3 upregulation [43].
It is clear that cytokines are also essential to Treg development. The
existing data from human thymus show that IL-2 promotes Treg dif-
ferentiation both at the DP and CD4 SP stage [25,44]. Given the high
expression of CD25 IL-2 is likely to be the most important second signal,
following TCR-mediated positive selection and CD25 upregulation.
Other common γ chain cytokines also have an impact [45]. We and
others have shown that IL-7 signalling leads to FOXP3 upregulation in
human thymocytes, and at the DP stage induces BCL-2 expression and
promotes the selective survival of FOXP3+ cells [38]. Interleukin-15 is
also likely to have similar eﬀects, but may aﬀect Treg diﬀerentiation
already at an earlier stage than IL-2 and IL-7 [25].
Together with earlier studies, our data are consistent with a devel-
opmental pathway of human Tregs that starts already at the DP stage, if
not earlier. We have suggested in the earlier study that divergence to
the Treg lineage takes place at the DP CD3low to CD3high transition,
driven by TCR-mediated positive selection [25]. Nothing as yet is
known of the Treg-selecting antigens in the human thymus, however,
and likewise there is no direct evidence that human Tregs are auto-
reactive. Similarly to that reported in mice, homeostatic cytokines
provide a crucial second signal, as well as promote Treg survival, and
the role of IL-2 at least is probably nonredundant [25,44]. At the CD4
SP stage the number of Tregs increases, and this increase is possibly also
augmented by further conversion of FOXP3- CD4SP thymocytes. How-
ever, if the human Treg commitment indeed takes place at the cortical
DP stage, then the antigens and signals necessary for it may also be
found in the thymic cortex.
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